Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries
BackgroundSurgical therapy of breast cancer and bone metastasis can effectively improve the prognosis of breast cancer. However, after the first operation, the relationship between preoperative indicators and outcomes in patients who underwent metastatic bone surgery remained to be studied. Purpose...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.693689/full |
id |
doaj-4b195037f1914717922140c667f4f0d6 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Haochen Mou Haochen Mou Haochen Mou Zhan Wang Zhan Wang Zhan Wang Wenkan Zhang Wenkan Zhang Wenkan Zhang Guoqi Li Guoqi Li Guoqi Li Hao Zhou Hao Zhou Hao Zhou Eloy Yinwang Eloy Yinwang Eloy Yinwang Fangqian Wang Fangqian Wang Fangqian Wang Hangxiang Sun Hangxiang Sun Hangxiang Sun Yucheng Xue Yucheng Xue Yucheng Xue Zenan Wang Zenan Wang Zenan Wang Tao Chen Tao Chen Tao Chen Xupeng Chai Xupeng Chai Xupeng Chai Hao Qu Hao Qu Hao Qu Peng Lin Peng Lin Peng Lin Wangsiyuan Teng Wangsiyuan Teng Wangsiyuan Teng Binghao Li Binghao Li Binghao Li Zhaoming Ye Zhaoming Ye Zhaoming Ye |
spellingShingle |
Haochen Mou Haochen Mou Haochen Mou Zhan Wang Zhan Wang Zhan Wang Wenkan Zhang Wenkan Zhang Wenkan Zhang Guoqi Li Guoqi Li Guoqi Li Hao Zhou Hao Zhou Hao Zhou Eloy Yinwang Eloy Yinwang Eloy Yinwang Fangqian Wang Fangqian Wang Fangqian Wang Hangxiang Sun Hangxiang Sun Hangxiang Sun Yucheng Xue Yucheng Xue Yucheng Xue Zenan Wang Zenan Wang Zenan Wang Tao Chen Tao Chen Tao Chen Xupeng Chai Xupeng Chai Xupeng Chai Hao Qu Hao Qu Hao Qu Peng Lin Peng Lin Peng Lin Wangsiyuan Teng Wangsiyuan Teng Wangsiyuan Teng Binghao Li Binghao Li Binghao Li Zhaoming Ye Zhaoming Ye Zhaoming Ye Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries Frontiers in Oncology breast cancer bone metastasis prognosis surgeries Cox regression nomogram |
author_facet |
Haochen Mou Haochen Mou Haochen Mou Zhan Wang Zhan Wang Zhan Wang Wenkan Zhang Wenkan Zhang Wenkan Zhang Guoqi Li Guoqi Li Guoqi Li Hao Zhou Hao Zhou Hao Zhou Eloy Yinwang Eloy Yinwang Eloy Yinwang Fangqian Wang Fangqian Wang Fangqian Wang Hangxiang Sun Hangxiang Sun Hangxiang Sun Yucheng Xue Yucheng Xue Yucheng Xue Zenan Wang Zenan Wang Zenan Wang Tao Chen Tao Chen Tao Chen Xupeng Chai Xupeng Chai Xupeng Chai Hao Qu Hao Qu Hao Qu Peng Lin Peng Lin Peng Lin Wangsiyuan Teng Wangsiyuan Teng Wangsiyuan Teng Binghao Li Binghao Li Binghao Li Zhaoming Ye Zhaoming Ye Zhaoming Ye |
author_sort |
Haochen Mou |
title |
Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries |
title_short |
Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries |
title_full |
Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries |
title_fullStr |
Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries |
title_full_unstemmed |
Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries |
title_sort |
clinical features and serological markers risk model predicts overall survival in patients undergoing breast cancer and bone metastasis surgeries |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-09-01 |
description |
BackgroundSurgical therapy of breast cancer and bone metastasis can effectively improve the prognosis of breast cancer. However, after the first operation, the relationship between preoperative indicators and outcomes in patients who underwent metastatic bone surgery remained to be studied. Purpose 1. Recognize clinical and laboratory prognosis factors available to clinical doctors before the operation for bone metastatic breast cancer patients. 2. Develop a risk prediction model for 3-year postoperative survival in patients with breast cancer bone metastasis.MethodsFrom 2014 to 2020, patients who suffered from breast cancer bone metastasis and received therapeutic procedures in our institution were included for analyses (n=145). For patients who underwent both breast cancer radical surgery and bone metastasis surgery, comprehensive datasets of the parameters of interest (clinical features, laboratory factors, and patient prognoses) were collected (n=69). We performed Multivariate Cox regression to identify factors that were associated with postoperative outcome. 3-year survival prediction model and nomograms were established by 100 bootstrapping. Its benefit was evaluated by calibration plot, C-index, and decision curve analysis. The Surveillance, Epidemiology, and End Results database was also used for external validation.ResultsRadiotherapy for primary cancer, pathological type of metastatic breast cancer, lymph node metastasis, elevated serum alkaline phosphatase, lactate dehydrogenase were associated with postoperative prognosis. Pathological types of metastatic breast cancer, multiple bone metastasis, organ metastases, and elevated serum lactate dehydrogenase were associated with 3-year survival. Then those significant variables and serum alkaline phosphatase counts were integrated to construct nomograms for 3-year survival. The C-statistic of the established predictive model was 0.83. The calibration plot presents a graphical representation of calibration. In the decision curve analysis, the benefits are higher than those of the extreme curve. The receiver operating characteristic of the external validation of the model was 0.82, indicating a favored fitting degree of the two models.ConclusionOur study suggests that several clinical features and serological markers can predict the overall survival among the patients who are about to receive bone metastasis surgery after breast cancer surgery. The model can guide the preoperative evaluation and clinical decision-making for patients. Level of evidence Level III, prognostic study. |
topic |
breast cancer bone metastasis prognosis surgeries Cox regression nomogram |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.693689/full |
work_keys_str_mv |
AT haochenmou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT haochenmou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT haochenmou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT zhanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT zhanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT zhanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT wenkanzhang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT wenkanzhang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT wenkanzhang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT guoqili clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT guoqili clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT guoqili clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT haozhou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT haozhou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT haozhou clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT eloyyinwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT eloyyinwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT eloyyinwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT fangqianwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT fangqianwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT fangqianwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT hangxiangsun clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT hangxiangsun clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT hangxiangsun clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT yuchengxue clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT yuchengxue clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT yuchengxue clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT zenanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT zenanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT zenanwang clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT taochen clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT taochen clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT taochen clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT xupengchai clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT xupengchai clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT xupengchai clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT haoqu clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT haoqu clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT haoqu clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT penglin clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT penglin clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT penglin clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT wangsiyuanteng clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT wangsiyuanteng clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT wangsiyuanteng clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT binghaoli clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT binghaoli clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT binghaoli clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT zhaomingye clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT zhaomingye clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries AT zhaomingye clinicalfeaturesandserologicalmarkersriskmodelpredictsoverallsurvivalinpatientsundergoingbreastcancerandbonemetastasissurgeries |
_version_ |
1717377560409538560 |
spelling |
doaj-4b195037f1914717922140c667f4f0d62021-09-17T05:27:45ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.693689693689Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis SurgeriesHaochen Mou0Haochen Mou1Haochen Mou2Zhan Wang3Zhan Wang4Zhan Wang5Wenkan Zhang6Wenkan Zhang7Wenkan Zhang8Guoqi Li9Guoqi Li10Guoqi Li11Hao Zhou12Hao Zhou13Hao Zhou14Eloy Yinwang15Eloy Yinwang16Eloy Yinwang17Fangqian Wang18Fangqian Wang19Fangqian Wang20Hangxiang Sun21Hangxiang Sun22Hangxiang Sun23Yucheng Xue24Yucheng Xue25Yucheng Xue26Zenan Wang27Zenan Wang28Zenan Wang29Tao Chen30Tao Chen31Tao Chen32Xupeng Chai33Xupeng Chai34Xupeng Chai35Hao Qu36Hao Qu37Hao Qu38Peng Lin39Peng Lin40Peng Lin41Wangsiyuan Teng42Wangsiyuan Teng43Wangsiyuan Teng44Binghao Li45Binghao Li46Binghao Li47Zhaoming Ye48Zhaoming Ye49Zhaoming Ye50Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaOrthopedics Research Institute of Zhejiang University, Hangzhou, ChinaKey Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Province, Hangzhou, ChinaBackgroundSurgical therapy of breast cancer and bone metastasis can effectively improve the prognosis of breast cancer. However, after the first operation, the relationship between preoperative indicators and outcomes in patients who underwent metastatic bone surgery remained to be studied. Purpose 1. Recognize clinical and laboratory prognosis factors available to clinical doctors before the operation for bone metastatic breast cancer patients. 2. Develop a risk prediction model for 3-year postoperative survival in patients with breast cancer bone metastasis.MethodsFrom 2014 to 2020, patients who suffered from breast cancer bone metastasis and received therapeutic procedures in our institution were included for analyses (n=145). For patients who underwent both breast cancer radical surgery and bone metastasis surgery, comprehensive datasets of the parameters of interest (clinical features, laboratory factors, and patient prognoses) were collected (n=69). We performed Multivariate Cox regression to identify factors that were associated with postoperative outcome. 3-year survival prediction model and nomograms were established by 100 bootstrapping. Its benefit was evaluated by calibration plot, C-index, and decision curve analysis. The Surveillance, Epidemiology, and End Results database was also used for external validation.ResultsRadiotherapy for primary cancer, pathological type of metastatic breast cancer, lymph node metastasis, elevated serum alkaline phosphatase, lactate dehydrogenase were associated with postoperative prognosis. Pathological types of metastatic breast cancer, multiple bone metastasis, organ metastases, and elevated serum lactate dehydrogenase were associated with 3-year survival. Then those significant variables and serum alkaline phosphatase counts were integrated to construct nomograms for 3-year survival. The C-statistic of the established predictive model was 0.83. The calibration plot presents a graphical representation of calibration. In the decision curve analysis, the benefits are higher than those of the extreme curve. The receiver operating characteristic of the external validation of the model was 0.82, indicating a favored fitting degree of the two models.ConclusionOur study suggests that several clinical features and serological markers can predict the overall survival among the patients who are about to receive bone metastasis surgery after breast cancer surgery. The model can guide the preoperative evaluation and clinical decision-making for patients. Level of evidence Level III, prognostic study.https://www.frontiersin.org/articles/10.3389/fonc.2021.693689/fullbreast cancerbone metastasisprognosissurgeriesCox regressionnomogram |